CD155 in Bladder Cancer

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

NCT05531123 ·Status: RECRUITING ·Phase: PHASE2

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

NCT05356351 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

NCT06820255 ·Status: RECRUITING ·Phase: PHASE4

An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer

NCT05559177 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

NCT05297552 ·Status: RECRUITING ·Phase: PHASE2

A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer

NCT07204496 ·Status: NOT_YET_RECRUITING

A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

NCT07342517 ·Status: WITHDRAWN ·Phase: PHASE3

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

NCT06488222 ·Status: RECRUITING ·Phase: PHASE2

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

NCT05595408 ·Status: RECRUITING

Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup

NCT06153849 ·Status: NOT_YET_RECRUITING

Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy

NCT04943094 ·Status: ACTIVE_NOT_RECRUITING

Establishment and Validation of an Early Diagnostic Model for Bladder Cancer Based on Serum and Urine Metabolomics

NCT04966962 ·Status: UNKNOWN

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

NCT06187506 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

NCT07332351 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02657486 ·Status: COMPLETED ·Phase: NA

Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale

NCT07051083 ·Status: RECRUITING

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

NCT03473730 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer

NCT07261592 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer

NCT02861196 ·Status: COMPLETED ·Phase: NA

DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC

NCT07207824 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Role of Microbiome in BCG Responsiveness Prediction

NCT05204199 ·Status: RECRUITING

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

NCT01589094 ·Status: COMPLETED ·Phase: PHASE2

An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

NCT04492293 ·Status: RECRUITING ·Phase: PHASE2

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

NCT06031584 ·Status: RECRUITING ·Phase: PHASE1/PHASE2